

Name of the Issuer:		Pramodini Medicare Limited	Last updated on	19.08.2026												
1	Type of Issue (IPO / FPO)															
2	Issue Size (Rs. Cr)*															
	- Fresh Issue Size (Rs. Cr)	63.13														
	- Offer for Sale Size (Rs. Cr)	5.90														
	*Source: Prospectus dated August 17, 2026 and Final Post issue report dated August 20, 2026															
3	Grade of issue along with name of the rating agency															
	Name	Not Applicable														
	Grade	Not Applicable														
4	Subscription Level (Number of times)		3.13*													
	Source: Final Post issue report dated August 20, 2026															
	*The above figure is after technical rejections															
5	QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges															
	<table><tr><th>Particulars</th><th>%</th></tr><tr><td>(i) allotment in the issue ⁽¹⁾</td><td>11.49%</td></tr><tr><td>(ii) at the end of 1st Quarter immediately after the listing*</td><td>Not Available</td></tr><tr><td>(iii) at the end of 1st FY (March 31, 2026)*</td><td>Not Available</td></tr><tr><td>(iv) at the end of 2nd FY (March 31, 2027)*</td><td>Not Available</td></tr><tr><td>(v) at the end of 3rd FY (March 31, 2028)*</td><td>Not Available</td></tr></table>				Particulars	%	(i) allotment in the issue ⁽¹⁾	11.49%	(ii) at the end of 1st Quarter immediately after the listing*	Not Available	(iii) at the end of 1st FY (March 31, 2026)*	Not Available	(iv) at the end of 2nd FY (March 31, 2027)*	Not Available	(v) at the end of 3rd FY (March 31, 2028)*	Not Available
Particulars	%															
(i) allotment in the issue ⁽¹⁾	11.49%															
(ii) at the end of 1st Quarter immediately after the listing*	Not Available															
(iii) at the end of 1st FY (March 31, 2026)*	Not Available															
(iv) at the end of 2nd FY (March 31, 2027)*	Not Available															
(v) at the end of 3rd FY (March 31, 2028)*	Not Available															
	*QIB Holding not disclosed as reporting for the relevant fiscal year has not been completed.															
	(1) Source: Basis of Allotment															
6	Financials of the issuer (Standalone)															
	(In Rs. Lacs)															
	Parameters	1st FY (March 31, 2027)*	2nd FY (March 31, 2028)*	3rd FY (March 31, 2029)*												
	Income from operations	Not Available	Not Available	Not Available												
	Net Profit for the period	Not Available	Not Available	Not Available												
	Paid-up equity share capital	Not Available	Not Available	Not Available												
	Reserves excluding revaluation reserves	Not Available	Not Available	Not Available												
	*Financials not disclosed as reporting for the relevant fiscal year has not been completed.															
7	Trading Status in the scrip of the issuer															
	Company's Equity Shares are listed on NSE Emerge															
	The Shares have not been suspended or delisted.															
	<table><tr><th>Particulars</th><th>Status</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2027)*</td><td>Not Available</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2028)*</td><td>Not Available</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2029)*</td><td>Not Available</td></tr></table>				Particulars	Status	(i) at the end of 1st FY (March 31, 2027)*	Not Available	(ii) at the end of 2nd FY (March 31, 2028)*	Not Available	(iii) at the end of 3rd FY (March 31, 2029)*	Not Available				
Particulars	Status															
(i) at the end of 1st FY (March 31, 2027)*	Not Available															
(ii) at the end of 2nd FY (March 31, 2028)*	Not Available															
(iii) at the end of 3rd FY (March 31, 2029)*	Not Available															
	*Trading status not disclosed as the relevant fiscal year has not been completed.															
8	Change in Directors of issuer from the disclosures in the offer document															
	<table><tr><th>Particulars</th><th>Name of the Director</th><th>Appointed / Resigned</th></tr><tr><td>(i) at the end of 1st FY (March 31, 2027)*</td><td>-</td><td>-</td></tr><tr><td>(ii) at the end of 2nd FY (March 31, 2028)*</td><td>-</td><td>-</td></tr><tr><td>(iii) at the end of 3rd FY (March 31, 2029)*</td><td>-</td><td>-</td></tr></table>				Particulars	Name of the Director	Appointed / Resigned	(i) at the end of 1st FY (March 31, 2027)*	-	-	(ii) at the end of 2nd FY (March 31, 2028)*	-	-	(iii) at the end of 3rd FY (March 31, 2029)*	-	-
Particulars	Name of the Director	Appointed / Resigned														
(i) at the end of 1st FY (March 31, 2027)*	-	-														
(ii) at the end of 2nd FY (March 31, 2028)*	-	-														
(iii) at the end of 3rd FY (March 31, 2029)*	-	-														
	Source: Stock Exchange Filings															
	* Changes in Directors of Issuer not updated as the relevant financial years have not been completed															

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

	(Rs. Crore)
Objects of the Fresh Issue	Amount
Funding of capital expenditure for purchase of Medical Equipments towards Existing and Proposed Diagnostic Centres	45.14
General corporate purposes	10.75
Total	55.89

Source: Prospectus dated August 17, 2026

(ii) Actual utilization

	(Rs. Crore)
Objects of the Fresh Issue	Amount
Funding of capital expenditure requirements of the Company towards setting up of the proposed Manufacturing Unit IV and upgradation of existing units at manufacturing facility in Rajkot, Gujarat	Not Available
Repayment or prepayment, in full or in part, of borrowings availed by our Company from banks, financial institutions and non-banking financial companies	Not Available
General corporate purposes	Not Available
Total	Not Available

(iii) Reasons for deviation, if any Not applicable

11 Comments of monitoring agency

(a) Comments on use of funds	Not applicable
(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	
(c) Any other reservations expressed by the monitoring agency about the end use of funds	

12 Pricing Data

Issue Price (Rs.):	118
Designated Stock Exchange:	NSE
Listing Date:	19-Aug-26

Price parameters	At close of listing day (August 19, 2026)	At close of 30th calendar day from listing day (September 18, 2026) ⁽¹⁾	At close of 90th calendar day from listing day (November 19, 2026) ⁽²⁾	As at the end of 1st FY after the listing of the issue (March 31, 2027)		
				Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	122	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50*	24078	Not Available	Not Available	Not Available	Not Available	Not Available

Price parameters	As at the end of 2nd FY after the listing of the issue (March 31, 2028) ⁽³⁾⁽⁴⁾			As at the end of 3rd FY after the listing of the issue (March 31, 2029) ⁽³⁾⁽⁴⁾		

	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on NSE	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
NIFTY 50*	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available

*Being index of NSE, the designated stock exchange

Note:

(1) 30th calendar day shall be taken as listing date plus 29 calendar days.

(2) 90th calendar day shall be taken as listing date plus 89 calendar days.

(3) High and Low based on intra day prices

(4) Pricing data not disclosed as the relevant fiscal year has not completed

(5) In case of any reporting day falling on a holiday, previous trading day prices has been disclosed.

13 Basis for Issue Price-

Accounting ratio	As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2027)	At the end of 2nd FY (March 31, 2028) ⁽²⁾	At the end of 3rd FY (March 31, 2029) ⁽²⁾
EPS	Issuer:	10.41	Not Available	Not Available
	Peer Group:			
	Invicta Diagnostic Limited	4.9	Not Available	Not Available
	Krsnaa Diagnostic Limited	31.3	Not Available	Not Available
	Star Imaging & Path Labs Limited	11.05	Not Available	Not Available
Price to Earnings Ratio (P/E)	Issuer:	11.34	Not Available	Not Available
	Peer Group:			
	Invicta Diagnostic Limited	14.90	Not Available	Not Available
	Krsnaa Diagnostic Limited	18.38	Not Available	Not Available
	Star Imaging & Path Labs Limited	8.64	Not Available	Not Available
NAV	Issuer:	31.84	Not Available	Not Available
	Peer Group:			
	Invicta Diagnostic Limited	39.71	Not Available	Not Available
	Krsnaa Diagnostic Limited	302.23	Not Available	Not Available
	Star Imaging & Path Labs Limited	66.65	Not Available	Not Available
RoNW(%)	Issuer:	32.69%	Not Available	Not Available
	Peer Group:			
	Invicta Diagnostic Limited	9.76%	Not Available	Not Available
	Krsnaa Diagnostic Limited	10.35%	Not Available	Not Available
	Star Imaging & Path Labs Limited	16.58%	Not Available	Not Available

Notes:

(1) Sourced from Prospectus dated August 17, 2026

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above are/shall be calculated as follows:

(i) Earnings per Equity Share are computed in accordance with Accounting Standard 20 "earnings per Share" notified by the Companies (Accounting Standards) Rules, 2006.

(ii) NAV per share - Net asset value per Equity Share represents net worth as at the end of the Fiscal divided by the number of Equity Shares outstanding at the end of the Fiscal

(iii) P/E - Closing Market Price as of relevant fiscal year end / Basic EPS for the Fiscal

(iv) RoNW - Return on net worth (%) is net profit attributable to equity shareholders divided by net worth for the Fiscal

14 Any other material information

Date of disclosure to Designated Stock Exchange	Announcement
Not Applicable	Not Applicable

Disclaimer:

The information compiled herein is in accordance with the disclosure requirements with regard to the track record of the public issues managed by Smart Horizon Capital Advisors Private Limited ("Smart") arising out of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012. This information is gathered from the Prospectus of the Issuer, as amended, and from the filings made by the Issuer with National Stock Exchange of India Limited as applicable, from time to time, price-volume data available on the website of National Stock Exchange of India Limited, other sources as disclosed herein and information / clarifications provided by the Issuer.

While reasonable care has been taken to ensure that the information provided herein is accurate and is taken from the sources that we believe are reliable, the user of this information may independently verify the accuracy of the information before taking any decision based on the above information.